Evidence from credible sources supports the statement as accurate. Learn more in Methodology.
A settlement was reached between the FTC and Express Scripts that resolves the FTC lawsuit alleging Express Scripts’ conduct inflated insulin drug prices.
On Feb. 4, 2026 the Federal Trade Commission announced a consent agreement with Express Scripts, Inc. (ESI) that the agency said "resolves the Commission's lawsuit" alleging ESI used anticompetitive rebating practices that artificially inflated insulin list prices. The FTC case docket shows an Agreement Containing Consent Order and a Proposed Decision and Order were filed the same day and posted for public comment, and independent outlets (Reuters, CNBC) reported the settlement and its key terms. Verdict: True — primary FTC filings and the agency press release, corroborated by reputable news coverage, confirm the FTC reached and filed a settlement with Express Scripts addressing the insulin-pricing allegations (the agreement is a proposed consent order subject to public comment and finalization).